Exact sciences corporation stock.

MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of ...Determining the value of old vinyl records isn’t an exact science, according to Rare Records. A variety of factors go into determining the value of a record, and these factors are what give some vinyl albums a high value while others don’t ...23-Feb-2023 ... Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP). The 2030 ... The offer and sale of the 2030 Notes and any shares of common stock ...Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Exact Sciences (EXAS) Stock Price & Analysis ; Previous Close$66.3 ; Volume2.13M ; Average Volume (3M)1.45M ; Market Cap. $11.99B ; Enterprise Value$13.82B.Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

EXACT Sciences Corporation share price live 65.59, this page displays NASDAQ EXAS stock exchange data. ... Monitor the latest movements within the EXACT Sciences Corporation real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit …

Exact Sciences completed its $2.8 billion cash-and-stock merger with Genomic Health in November 2019, according to a press release. Through the deal, Genomic Health became a subsidiary of Exact ...Exact Sciences has an Altman Z-Score of 1.76 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Exact Sciences Corporation (EXAS) stock, including valuation metrics, financial numbers, share information and more.About EXAS. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday. The company is a leader in using diagnostics to screen ...MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.

MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ...

Dec 4, 2023 · Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress. MADISON, Wis. , …Get the latest news and real-time alerts from Exact Sciences Corporation (EXAS) stock at Seeking Alpha. ... EXAS Exact Sciences Corporation. Latest News. Follow $65.82-0.17 (-0.26%) ...May 18, 2023 · On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ... Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.

MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.22-Feb-2022 ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and …On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer (CRC) at 91% specificity, during the American College ...

Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...

Company profile page for Exact Sciences Corp including stock price, company news, executives, board members, and contact informationExact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.The Exact Sciences Corp NASDAQ: EXAS stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days.. Most of that value climb came yesterday, with the molecular diagnostic company's stock gaining 24.65% at the end of the trading session. Putting this figure into perspective is that the S&P 500 …Nov 1, 2023 · Third-quarter 2023 financial results. For the three-month period ended September 30, 2023, as compared to the same period of 2022 (where applicable): • Total revenue was $628.3 million, an increase of 20 percent. • Core revenue was $624.8 million, an increase of 23 percent. • Screening revenue was $472.0 million, an increase of 31 percent. 02-Aug-2022 ... MADISON, Wis., Aug. 2, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov. 01.Currently, Kevin T. Conroy occupies the position of Chairman, President & Chief Executive Officer at EXACT Sciences Corp. and President & Director at Genomic Health, Inc. (a subsidiary of EXACT Sciences Corp.). He is also on the board of 8 other companies. Kevin T. Conroy previously was Partner at McDermott Will & Emery LLP, Director at ...About Exact Sciences Corp. ... 2022 and 2021. Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was zero for the three and six months ended June 30, 2022, compared to $2.4 million and $102.8 million for the three and six months …Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ...

Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Gold 1,927.30 -14.20(-0.73%) Advertisement Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 65.27 …

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ...Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 30, 2023 · The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm ... Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended ...On December 30, 2022, the Board of Directors (the Board") of Exact Sciences Corporation (the Company") expanded the size of the Board from 9 to 10 members and elected D. Scott Coward to serve as a Class II member of the Board …Company profile page for Exact Sciences Corp including stock price, company news, press releases, executives, board members, and contact informationEXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings …03-Nov-2023 ... everyone excited? Whoo. The stock is up. That's good. ... Exact Sciences and chairman and CEO Kevin Conroy. ... sciences commitment to earlier ...Nov 30, 2023 · The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm ... Nov 30, 2022 · Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price-earnings ratio. Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | Nasdaq

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after ...Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com. About Exact Sciences Corp.Shares of medical diagnostic company Exact Sciences ( EXAS 1.49%) fell by a jaw-dropping 41% over the whole of 2021, according to data provided by S&P Global Market Intelligence. Although the ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...Instagram:https://instagram. autozone competitornyse hwmnyse wustock programs EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level …Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ... morgan stanely stockgfl. Stock Information · Financial Information · SEC Filings · Quarterly Results · Analyst Coverage ... © Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI ... etf shy MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Exact Sciences Corporation (NASDAQ:EXAS) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ETCompany Participants. Megan Jones - Investor Relations. Kevin Conroy - Chairman and Chief ...